Inspiris Resilia in the Pulmonary Position: The Need for Discussion and Collaboration of Results

The recently published study by Said and colleagues 1 Said S.M. Hiremath G. Aggarwal V. et al. Early concerning outcomes for the Edwards Inspiris Resilia bioprosthesis in the pulmonary position. Ann Thorac Surg. 2023; 115: 1000-1007 Abstract Full Text Full Text PDF Scopus (2) Google Scholar expressed concern with the Inspiris Resilia (IR) bioprosthesis (Edwards Lifescience LLC) in the pulmonary position. Of the reported cohort of 27 patients, 13 patients progressed to pulmonary regurgitation (PR) with a median time to appearance of 8 months postoperatively. Moderate or severe PR was present in 33% of the patients at 16 months. Early Concerning Outcomes for the Edwards Inspiris Resilia Bioprosthesis in the Pulmonary PositionThe Annals of Thoracic SurgeryVol. 115Issue 4PreviewThe Inspiris Resilia (Edwards Lifesciences LLC) bioprosthesis has gained widespread use in the aortic position; however no robust data are available about its use in the pulmonary position. Full-Text PDF Inspiris Resilia Early Failure in the Pulmonary Position: Is It the Technique or the Valve?The Annals of Thoracic SurgeryVol. 116Issue 3PreviewI would like to thank Knox and colleagues1 for their letter to the editor in regard to our recently published article2 discussing early concerning results of the Inspiris Resilia (IR) (Edwards Lifesciences) bioprosthesis in the pulmonary position. The authors reported briefly their early experience with the IR prosthesis in 21 adult patients with no or trivial prosthetic regurgitation (PR) in 13 patients (81%) at a median follow-up of 11 months. Full-Text PDF